Nonproteolytic Neuroprotection by Human Recombinant Tissue Plasminogen Activator
- 23 April 1999
- journal article
- other
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 284 (5414) , 647-650
- https://doi.org/10.1126/science.284.5414.647
Abstract
Human recombinant tissue plasminogen activator (tPA) may benefit ischemic stroke patients by dissolving clots. However, independent of thrombolysis, tPA may also have deleterious effects on neurons by promoting excitotoxicity. Zinc neurotoxicity has been shown to be an additional key mechanism in brain injuries. Hence, if tPA affects zinc neurotoxicity, this may provide additional insights into its effect on neuronal death. Independent of its proteolytic action, tPA markedly attenuated zinc-induced cell death in cortical culture, and, when injected into cerebrospinal fluid, also reduced kainate seizure–induced hippocampal neuronal death in adult rats.Keywords
This publication has 32 references indexed in Scilit:
- ZINC AND BRAIN INJURYAnnual Review of Neuroscience, 1998
- Hyperacute Stroke Therapy With Tissue Plasminogen ActivatorThe American Journal of Cardiology, 1997
- Neuroprotective Therapies In StrokeDrugs, 1997
- The Role of Zinc in Selective Neuronal Death After Transient Global Cerebral IschemiaScience, 1996
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995
- BDNF or IGF-I potentiates free radical-mediated injury in cortical cell culturesNeuroReport, 1995
- Staurosporine-Induced Neuronal ApoptosisExperimental Neurology, 1995
- Low levels of plasminogen in cerebrospinal fluid after intraventricular haemorrhage: a limiting factor for clot lysis?Acta Paediatrica, 1995
- AMPA receptor activation potentiates zinc neurotoxicityNeuron, 1993
- Purification of active human plasminogen activator inhibitor 1 from Escherichia coliEuropean Journal of Biochemistry, 1989